Effect of bromocriptine on glycemic control, risk of cardiovascular diseases and weight in patients with type 2 diabetes: a systematic review
Abstract Background Type 2 diabetes (T2DM) patients, including those in good glycemic control, have an increased risk of cardiovascular disease (CVD). Maintaining good glycemic control with drugs may reduce long-term CVD risk. Bromocriptine has been in clinical use for over 30 years, but the utility...
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMC
2023-07-01
|
| Series: | Diabetology & Metabolic Syndrome |
| Subjects: | |
| Online Access: | https://doi.org/10.1186/s13098-023-01073-2 |
| _version_ | 1797784471933550592 |
|---|---|
| author | Mulualem Tesfaye Birhan Teklie Mengie Ayele Fikire Wondimu Abebe Fiseha Nigussie Dgnew |
| author_facet | Mulualem Tesfaye Birhan Teklie Mengie Ayele Fikire Wondimu Abebe Fiseha Nigussie Dgnew |
| author_sort | Mulualem Tesfaye Birhan |
| collection | DOAJ |
| description | Abstract Background Type 2 diabetes (T2DM) patients, including those in good glycemic control, have an increased risk of cardiovascular disease (CVD). Maintaining good glycemic control with drugs may reduce long-term CVD risk. Bromocriptine has been in clinical use for over 30 years, but the utility of bromocriptine in the treatment of diabetes patients has been proposed more recently. Objective To summarize the available data regarding the effect of bromocriptine in T2DM management. Method A systematic literature search was conducted in the electronic databases, including Google Scholar, PubMed, Medline, and Science Direct, to locate studies that meet the objectives of this systematic review. Additional articles were included by conducting direct Google searches of the references cited by eligible articles located by the database search. The following search terms were used on PubMed “bromocriptine OR dopamine agonist AND diabetes mellitus OR hyperglycemia OR obese”. Result Eight studies were included in the final analysis. 6210 of the 9391 study participants received bromocriptine treatment, while 3183 received a placebo. The studies demonstrated that patients who took bromocriptine treatment had significantly reduced blood glucose and BMI, which is the main cardiovascular risk factor in T2DM patients. Conclusion Based on this systematic review, bromocriptine may be used for T2DM treatment for its cardiovascular risk reduction effect, especially body weight reduction. However, advanced study designs might be warranted. |
| first_indexed | 2024-03-13T00:40:22Z |
| format | Article |
| id | doaj.art-21bd9c6a9f3f409f95ef2945384999b9 |
| institution | Directory Open Access Journal |
| issn | 1758-5996 |
| language | English |
| last_indexed | 2024-03-13T00:40:22Z |
| publishDate | 2023-07-01 |
| publisher | BMC |
| record_format | Article |
| series | Diabetology & Metabolic Syndrome |
| spelling | doaj.art-21bd9c6a9f3f409f95ef2945384999b92023-07-09T11:20:02ZengBMCDiabetology & Metabolic Syndrome1758-59962023-07-011511710.1186/s13098-023-01073-2Effect of bromocriptine on glycemic control, risk of cardiovascular diseases and weight in patients with type 2 diabetes: a systematic reviewMulualem Tesfaye Birhan0Teklie Mengie Ayele1Fikire Wondimu Abebe2Fiseha Nigussie Dgnew3Department of Pharmacy, College of Health Science, Debre Tabor UniversityDepartment of Pharmacy, College of Health Science, Debre Tabor UniversityDepartment of Pharmacology and Clinical Pharmacy, School of Pharmacy, College of health sciences, Addis Ababa UniversityDepartment of Pharmacy, College of Health Science, Debre Tabor UniversityAbstract Background Type 2 diabetes (T2DM) patients, including those in good glycemic control, have an increased risk of cardiovascular disease (CVD). Maintaining good glycemic control with drugs may reduce long-term CVD risk. Bromocriptine has been in clinical use for over 30 years, but the utility of bromocriptine in the treatment of diabetes patients has been proposed more recently. Objective To summarize the available data regarding the effect of bromocriptine in T2DM management. Method A systematic literature search was conducted in the electronic databases, including Google Scholar, PubMed, Medline, and Science Direct, to locate studies that meet the objectives of this systematic review. Additional articles were included by conducting direct Google searches of the references cited by eligible articles located by the database search. The following search terms were used on PubMed “bromocriptine OR dopamine agonist AND diabetes mellitus OR hyperglycemia OR obese”. Result Eight studies were included in the final analysis. 6210 of the 9391 study participants received bromocriptine treatment, while 3183 received a placebo. The studies demonstrated that patients who took bromocriptine treatment had significantly reduced blood glucose and BMI, which is the main cardiovascular risk factor in T2DM patients. Conclusion Based on this systematic review, bromocriptine may be used for T2DM treatment for its cardiovascular risk reduction effect, especially body weight reduction. However, advanced study designs might be warranted.https://doi.org/10.1186/s13098-023-01073-2Dopamine agonistDiabetes mellitusBromocriptineGlycemic control |
| spellingShingle | Mulualem Tesfaye Birhan Teklie Mengie Ayele Fikire Wondimu Abebe Fiseha Nigussie Dgnew Effect of bromocriptine on glycemic control, risk of cardiovascular diseases and weight in patients with type 2 diabetes: a systematic review Diabetology & Metabolic Syndrome Dopamine agonist Diabetes mellitus Bromocriptine Glycemic control |
| title | Effect of bromocriptine on glycemic control, risk of cardiovascular diseases and weight in patients with type 2 diabetes: a systematic review |
| title_full | Effect of bromocriptine on glycemic control, risk of cardiovascular diseases and weight in patients with type 2 diabetes: a systematic review |
| title_fullStr | Effect of bromocriptine on glycemic control, risk of cardiovascular diseases and weight in patients with type 2 diabetes: a systematic review |
| title_full_unstemmed | Effect of bromocriptine on glycemic control, risk of cardiovascular diseases and weight in patients with type 2 diabetes: a systematic review |
| title_short | Effect of bromocriptine on glycemic control, risk of cardiovascular diseases and weight in patients with type 2 diabetes: a systematic review |
| title_sort | effect of bromocriptine on glycemic control risk of cardiovascular diseases and weight in patients with type 2 diabetes a systematic review |
| topic | Dopamine agonist Diabetes mellitus Bromocriptine Glycemic control |
| url | https://doi.org/10.1186/s13098-023-01073-2 |
| work_keys_str_mv | AT mulualemtesfayebirhan effectofbromocriptineonglycemiccontrolriskofcardiovasculardiseasesandweightinpatientswithtype2diabetesasystematicreview AT tekliemengieayele effectofbromocriptineonglycemiccontrolriskofcardiovasculardiseasesandweightinpatientswithtype2diabetesasystematicreview AT fikirewondimuabebe effectofbromocriptineonglycemiccontrolriskofcardiovasculardiseasesandweightinpatientswithtype2diabetesasystematicreview AT fisehanigussiedgnew effectofbromocriptineonglycemiccontrolriskofcardiovasculardiseasesandweightinpatientswithtype2diabetesasystematicreview |